The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) is a huge mover today! About 733,136 shares traded hands. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has declined 43.63% since April 8, 2016 and is downtrending. It has underperformed by 49.28% the S&P500.
The move comes after 9 months positive chart setup for the $1.47B company. It was reported on Nov, 10 by Barchart.com. We have $50.96 PT which if reached, will make NASDAQ:PCRX worth $588.00M more.
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Ratings Coverage
Out of 10 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 7 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 70% are positive. Pacira Pharmaceuticals has been the topic of 20 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Tuesday, September 29 by Nomura. The firm earned “Buy” rating on Thursday, November 3 by Mizuho. Mizuho initiated Pacira Pharmaceuticals Inc (NASDAQ:PCRX) on Tuesday, April 19 with “Buy” rating. The company was maintained on Thursday, August 20 by Wedbush. Brean Capital maintained the shares of PCRX in a report on Friday, February 26 with “Buy” rating. The company was maintained on Tuesday, May 3 by Mizuho. The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) earned “Outperform” rating by Wedbush on Wednesday, October 19. On Tuesday, January 5 the stock rating was reinitiated by JMP Securities with “Mkt Outperform”. The firm has “Underperform” rating by BMO Capital Markets given on Wednesday, June 29. The rating was reinitiated by Brean Capital with “Hold” on Friday, October 7.
According to Zacks Investment Research, “Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc. is based in New Jersey.”
Insitutional Activity: The institutional sentiment increased to 1.34 in 2016 Q2. Its up 0.39, from 0.95 in 2016Q1. The ratio increased, as 41 funds sold all Pacira Pharmaceuticals Inc shares owned while 39 reduced positions. 36 funds bought stakes while 71 increased positions. They now own 39.74 million shares or 7.79% less from 43.10 million shares in 2016Q1.
Sarissa Mgmt Ltd Partnership owns 653,000 shares or 6.25% of their US portfolio. The New York-based Citigroup Inc has invested 0% in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). The Switzerland-based Credit Suisse Ag has invested 0% in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Moreover, Bnp Paribas Arbitrage Sa has 0% invested in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) for 1,444 shares. Legacy Prns last reported 23,200 shares in the company. Susquehanna International Grp Llp accumulated 0% or 58,870 shares. Stephens Investment Gru Llc has 0.64% invested in the company for 579,210 shares. Parametric Port Associates Ltd Liability owns 17,723 shares or 0% of their US portfolio. Moreover, Kbc Grp Nv has 0% invested in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) for 511 shares. Citadel Advsr Ltd Liability reported 536,602 shares or 0.02% of all its holdings. Vanguard Group accumulated 2.59 million shares or 0.01% of the stock. Pnc Financial Svcs Gru Inc, a Pennsylvania-based fund reported 7,180 shares. Schroder Inv Mngmt Grp has 0.03% invested in the company for 479,200 shares. Barclays Pcl accumulated 23 shares or 0% of the stock. California State Teachers Retirement owns 76,416 shares or 0.01% of their US portfolio.
Insider Transactions: Since June 6, 2016, the stock had 0 insider purchases, and 7 insider sales for $2.03 million net activity. The insider Scibetta James S sold $1.13 million. Kronenfeld Mark A. sold 900 shares worth $42,255. Riker Lauren Bullaro sold 938 shares worth $44,706. On Monday, June 6 Williams Kristen Marie sold $28,319 worth of the stock or 600 shares. 15,000 shares were sold by STACK DAVID M, worth $679,800 on Monday, August 15. The insider Brege Laura sold 1,000 shares worth $46,950. HASTINGS PAUL J had sold 1,136 shares worth $53,335 on Monday, June 6.
More recent Pacira Pharmaceuticals Inc (NASDAQ:PCRX) news were published by: Nasdaq.com which released: “Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in November” on November 10, 2016. Also Fool.com published the news titled: “Why Pacira Pharmaceuticals, Inc. Shares Are Spiking 21% Today” on August 04, 2016. Seekingalpha.com‘s news article titled: “Pacira: Exparel’s Inflection Point Moves To 2017” with publication date: November 09, 2016 was also an interesting one.
PCRX Company Profile
Pacira Pharmaceuticals, Inc., incorporated on December 22, 2006, is a specialty pharmaceutical company. The Firm is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. The Company’s primary focus lies in the development of non-opioid products for postsurgical pain control. The Company’s lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company makes for its commercial partners, as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.